P. Tolosa Ortega - 3Medical Oncology Department, SOLTI / Hospital Universitario 12 de Octubre

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

N. Martínez-Jañez,M. Bellet Ezquerra, L. M. Manso Sanchez,F. Henao Carrasco,A. Anton Torres, S. Morales,P. Tolosa Ortega, V. L. Obadia Gil, T. Sampedro, R. Andrés Conejero, L. Calvo-Martinez, E. Galve-Calvo,

Breast Cancer Research and Treatment (2024)

引用0浏览0引用

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Breast Cancer Research and Treatmentpp.1-12, (2024)

引用0浏览0引用

First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN

N Martínez-Jañez,M Bellet Ezquerra, L M Manso Sanchez,F Henao Carrasco,A Anton Torres, S Morales,P Tolosa Ortega, V L Obadia Gil, T Sampedro, R Andrés Conejero, L Calvo-Martinez, E Galve-Calvo,

Breast cancer research and treatment (2024)

引用0浏览0WOS引用

First-line therapy with palbociclib in patients with advanced HR⁺/HER2^- breast cancer: The real-life study PALBOSPAIN

N. Martinez-Janez,M. Bellet Ezquerra,L. M. Manso Sanchez,F. Henao Carrasco,A. Anton Torres, S. Morales,P. Tolosa Ortega, V. L. Obadia Gil, T. Sampedro, R. Andres Conejero, L. Calvo-Martinez, E. Galve-Calvo,

BREAST CANCER RESEARCH AND TREATMENT (2024)

引用0浏览0引用

155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

M. Oliveira, T. Pascual, G. Villacampa, M. Munoz,A. Perello Martorell,M.E. Perez Lopez,K. Amillano Parraga,X. González Farre, C. Martinez Vila,P. Tolosa Ortega,M. Borrell Puy,M. Margeli Vila,

ESMO Openno. 1 (2023): 101494-101494

引用0浏览0引用

406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC

S. Lopez-Tarruella Cobo, A. Stradella,P. Tolosa Ortega, S. Antolín-Novoa, M. Santisteban Eslava, J. Garcia-Corbacho, A.L. Guerrero Zotano,M. Ruiz Borrego, M. Muñoz Caffarel, N. Losic, E. Jaensson Gyllenbäck, P. Skoog,

Annals of Oncology (2023): S353-S353

引用0浏览0引用

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial